Investors and Media

Investors and Media

Stay informed about Cambium Bio's latest financial performance, corporate developments, and strategic initiatives. Access our recent financial reports, press releases, and investor presentations, and discover upcoming events to engage with our leadership team. As a publicly-listed company, we are committed to maintaining transparent and timely communication with our shareholders, analysts, and media stakeholders.

Stay informed about Cambium Bio's latest financial performance, corporate developments, and strategic initiatives. Access our recent financial reports, press releases, and investor presentations, and discover upcoming events to engage with our leadership team. As a publicly-listed company, we are committed to maintaining transparent and timely communication with our shareholders, analysts, and media stakeholders.

Stay informed about Cambium Bio's latest financial performance, corporate developments, and strategic initiatives. Access our recent financial reports, press releases, and investor presentations, and discover upcoming events to engage with our leadership team. As a publicly-listed company, we are committed to maintaining transparent and timely communication with our shareholders, analysts, and media stakeholders.

Corporate Profile

Corporate Presentation (July 2025)

Corporate Presentation (July 2025)

Jul 30, 2025

Jul 30, 2025

ASX Announcements

Quarterly Cashflow Report - Period ending 30 June 2025

Quarterly Cashflow Report - Period ending 30 June 2025

Jul 31, 2025

Jul 31, 2025

Cambium Bio Raises $2.12M via Fully-Subscribed Placement

Cambium Bio Raises $2.12M via Fully-Subscribed Placement

Jul 30, 2025

Jul 30, 2025

Cambium Bio Clears FDA Regulatory Hurdles to Commence Phase 3 Dosing for Elate Ocular

Cambium Bio Clears FDA Regulatory Hurdles to Commence Phase 3 Dosing for Elate Ocular

Jul 11, 2025

Jul 11, 2025

Cambium Bio Receives Ethics Approvals

Cambium Bio Receives Ethics Approvals

Jun 30, 2025

Jun 30, 2025

Quarterly Cashflow Report & Business Update-March 2024

Quarterly Cashflow Report & Business Update-March 2024

Apr 28, 2025

Apr 28, 2025

For all Cambium Bio Limited ASX market announcements, click here

Financial Information

Cambium Bio Limited Half Year Report (December 2024)

Cambium Bio Limited Half Year Report (December 2024)

Feb 27, 2025

Feb 27, 2025

Cambium Bio Limited Annual Report FY2024

Cambium Bio Limited Annual Report FY2024

Aug 30, 2024

Aug 30, 2024

Cambium Bio Limited Half Year Report (December 2023)

Cambium Bio Limited Half Year Report (December 2023)

Dec 31, 2023

Dec 31, 2023

Cambium Bio Limited Annual Report FY2023

Cambium Bio Limited Annual Report FY2023

Jun 30, 2023

Jun 30, 2023

News Releases

Regeneus trebles on back of merger deal (Sydney Morning Herald)

Regeneus trebles on back of merger deal (Sydney Morning Herald)

Apr 5, 2024

Apr 5, 2024

Cambium Bio to enter ASX through backdoor listing via merger with Regeneus to treat dry eye disease

Cambium Bio to enter ASX through backdoor listing via merger with Regeneus to treat dry eye disease

Feb 6, 2024

Feb 6, 2024

Events and Presentations

Meet Cambium Bio team at BIO International Convention in San Diego

Meet Cambium Bio team at BIO International Convention in San Diego

Apr 17, 2024

Apr 17, 2024